Drugs / Triflusal
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02904109 | Sep 2016 → Feb 2017 | — | University of Basel | Completed | No outcome recorded |
| Phase 2 | NCT02321852 | Jan → Nov 2015 | — | University of Basel | Completed | No outcome recorded |
| Phase 2 | NCT00162799 | Jul 2002 → Dec 2004 | — | J. Uriach and Company | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01612273 | Apr 2011 → Jan 2013 | vascular disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01174693 | Mar 2010 → Dec 2014 | cerebral infarction | Gangnam Severance Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02616497 Comparator | Sep 2015 → Feb 2017 | atherosclerotic cardiovascular disease | University of Ioannina | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triflusal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01174693 ↗ |
| Known as | 2-(acetyloxy)-4-(trifluoromethyl) benzoic acid | “Triflusal, 2-(acetyloxy)-4-(trifluoromethyl) benzoic acid, is an antiplatelet agent with a chemical structure similar to aspirin, but with a different pharmacokinetic and...” NCT02616497 ↗ |
| Known as | Disgren | “Once daily oral administration of 600 mg triflusal Disgren® for 7 days.” NCT02321852 ↗ |
| Action | Activate | “eNOS activating agent” NCT02321852 ↗ |
| Modality | Small molecule | “Triflusal is a salicylate compound” NCT01612273 ↗ |
| Route | Oral | “Mode of administration: oral” NCT01174693 ↗ |
| Target | PTGS1 | “Triflusal irreversibly inhibits COX-1 and reduces TxA2 production” NCT02616497 ↗ |